XG005 relieves OA symptoms in phase 2b study

The experimental, non-opioid, oral agent XG005 inhibits inflammatory and neuropathic signals in patients with knee osteoarthritis (OA). In a phase 2b trial, XG005 demonstrated robust and consistent efficacy in alleviating OA symptoms and was well tolerated, making this a promising treatment option for chronic OA.

XG005 is a non-opioid, dual-acting conjugated prodrug in development in oral and topical formulations. It inhibits inflammatory and neuropathic signals via the COX enzymes and the calcium subunit. Dr Leon Jiang (Xgene Pharmaceutical Lexington, MA, USA) presented the results of a randomised, double-blind, placebo-controlled, phase 2b trial evaluating oral XG005 for Chinese patients with knee OA [1]. The 318 participants, recruited from 22 sites, had moderate-to-severe OA pain and Kellgren-Lawrence (KL) grade II–III. They were randomised 2:1:2 to XG005 750 mg twice daily, 500 mg twice daily, or placebo. The primary efficacy endpoint was change from baseline in weekly Average Daily Walking pain after 4 weeks.

Average daily walking pain and Western Ontario and McMaster Universities Arthritis (WOMAC) index pain at baseline were 5.87 and 4.59, respectively, on a numerical scale of 0–10; Knee Injury and Osteoarthritis Outcome Score (KOOS) was 52.46. Almost half (43.2%) of the participants had painDETECT scores ≥13, indicating neuropathic pain components.

At week 4, Weekly Average Daily Walking pain in the XG005 750 mg group was significantly more reduced than in the placebo group: -2.3 versus -1.7 (P=0.0055). This difference was already significant after 1 week (P=0.0025). On the WOMAC Pain subscore, both doses of XG005 were significantly more effective compared with placebo: -2.2 (for both doses) versus 1.7 (750 mg: P=0.0054; 500 mg: P=0.0384). Both doses of XG005 were also superior to placebo in all other secondary efficacy endpoints. XG005 was safe and well-tolerated, with no drug-related serious adverse events. Rescue medication was barely used in the treatment or placebo arms.

1. Jiang L, et al. A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging and parallel-group study to evaluate the safety and efficacy of XG005 in subjects with painful osteoarthritis of the knee. Abstract L08, ACR Convergence 2024, 14-19 November, Washington DC, USA.

 

Medical writing support was provided by Michiel Tent

Copyright ©2024 Medicom Medical Publishers



Posted on 21 November 202421 November 2024